In order to explore the potential differential activity of nivolumab, pembrolizumab (targeting PD-1) and MPDL3280A (targeting PD-L1) according to the PD-L1 expression on cancer cells in melanoma, NSCLC and genitourinary cancers we conducted a sensitivity analysis of phase I, phase II and phase III trials. Here, CD274 is linked to non-small cell lung carcinoma.